Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Gibson

Internal Medicine Muncie, IN Medical Doctor

NPI 1528110764 CMS profile 250151

4000 W Woodway Dr, Muncie, IN 47304

Open in the dashboard

General payments

$9,532

773 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Gibson of Muncie, IN is reported in the CMS Open Payments database as having received $9,532 across 773 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16 1
2023 General $749 47
2022 General $2,286 169
2021 General $2,731 225
2020 General $1,794 143
2019 General $1,955 188

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Gibson
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Thomas Gibson were reported at $16. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Thomas Gibson Internal Medicine median Middle half National median
2019 $1,955 $159 $48–$570 $163
2020 $1,794 $119 $33–$402 $114
2021 $2,731 $135 $37–$521 $132
2022 $2,286 $141 $42–$496 $149
2023 $749 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $16 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,244 111 payments
  2. Novo Nordisk Inc $891 70 payments
  3. GlaxoSmithKline, LLC. $783 95 payments
  4. Lilly USA, LLC $704 64 payments
  5. Amgen Inc. $684 43 payments
  6. Astellas Pharma US Inc $609 29 payments
  7. AstraZeneca Pharmaceuticals LP $480 25 payments
  8. Amarin Pharma Inc. $424 26 payments
  9. Janssen Pharmaceuticals, Inc $407 33 payments
  10. Allergan Inc. $395 69 payments
  11. Other $2,910 208 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,391 770 payments
  2. Education $141 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $534 40 payments
  2. LINZESS $526 47 payments
  3. TRELEGY ELLIPTA $492 66 payments
  4. RYBELSUS $432 33 payments
  5. CREON $426 30 payments
  6. Repatha $410 20 payments
  7. XARELTO $407 33 payments
  8. MYRBETRIQ $403 24 payments
  9. FARXIGA $390 22 payments
  10. AIMOVIG $377 19 payments
  11. Other $8,655 719 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

34

Median for Internal Medicine: 777

Drug cost

$308

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metoprolol Succinate Generic 18 $179
Meloxicam Generic 16 $129

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

773 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record